Autoinflammatory & rare systemic diseases
Could tocilizumab be used in familial Mediterranean fever? A systematic review
Authors' conclusion
This review summarizes the current state of research, safety and efficacy of TCZ in FMF.
Study context
- Population
- Patients with Familial Mediterranean Fever (FMF) treated with tocilizumab (TCZ)14 articles
- Outcome
- Efficacy and safety of TCZ in the treatment of FMF
Methodological detailsPRISMA guidelines
- PRISMA guidelines
Pooled result
As reported in the abstract
Efficacy of TCZ in FMF
- Multicentre double-blind RCTs reported mixed results in FMF patients without AA amyloidosis
- Retrospective studies suggest TCZ may benefit FMF patients with established renal AA amyloidosis, potentially preventing progression and managing flares more effectively
- No available data on TCZ in paediatric FMF
- 14 articles: two double-blind RCTs, two retrospective studies and 10 case reports
Safety
Safety of TCZ
- Safe profile with no specific adverse events; data on use during pregnancy or breastfeeding lacking
Original publication
Could tocilizumab be used in familial Mediterranean fever? A systematic review. Rheumatology (Oxford). Published 1 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →